Tempus AI (TEM) has launched a new prostate test for metastatic hormone-sensitive prostate cancer patients, the company said Thursday.
The ArteraAI prostate test uses artificial intelligence to assess a patient's clinical data and biopsy images to estimate a patient's likelihood of prostate cancer-specific mortality, Tempus AI said.